A randomized, controlled, parallel group, double-blind, multi-centre, phase IIb study to assess safety and clinical activity of continued AFFITOPE AD02 vaccinations of patients who participated in the AFFITOPE AD02 phase II study AFF006.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Affitope AD02 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors AFFiRiS
- 23 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 17 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.
- 13 Feb 2013 New trial record